Cara Therapeutics (CARA) Reports Q2 Loss, Tops Revenue Estimates

Cara Therapeutics (CARA) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.68. This compares to loss of $0.58 per share a year ago. These figures are adjusted for non-recurring items.
This quarterly report represents an earnings surprise of 20.59%. A quarter ago, it was expected that this biotechnology company would post a loss of $0.63 per share when it actually produced a loss of $0.62, delivering a surprise of 1.59%.
Over the last four qua…

Click here to view the original article.